Practical issues and concepts in vagus nerve stimulation: a nursing review

Area of Science:

• Neurology
• Biomedical Engineering
• Medical Devices

Background:

• Epilepsy affects 0.5-1% of the U.S. population, with partial onset seizures being most common in adults.
• Approximately 20% of adult patients with partial onset seizures are refractory to antiepileptic drugs and experience side effects.
• Alternative treatments like the ketogenic diet and epilepsy surgery have limitations for adult patients.

Purpose of the Study:

• To evaluate vagus nerve stimulation (VNS) using the Neuro Cybernetic Prosthesis (NCP) system as a novel treatment for refractory partial onset seizures.
• To highlight the FDA approval of VNS as an adjunctive therapy for specific patient populations.

Main Methods:

• Vagus nerve stimulation (VNS) utilizing the Neuro Cybernetic Prosthesis (NCP) system.
• Adjunctive therapy for refractory partial onset seizures in adults and adolescents over 12 years of age.
• Clinical evaluation of seizure frequency reduction.

Main Results:

• Vagus nerve stimulation (VNS) with the NCP system demonstrates effectiveness in reducing seizure frequency.
• The U.S. Food and Drug Administration (FDA) approved the NCP system for VNS in 1997.
• Studies report similar positive outcomes in children younger than 12 years.

Conclusions:

• Vagus nerve stimulation (VNS) is a significant advancement in treating refractory epilepsy, offering an alternative to medication or surgery.
• The NCP system represents the first FDA-approved medical device for refractory seizure treatment.
• An estimated 10,000 patients have received VNS implants, indicating its clinical adoption and perceived efficacy.